Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Markus M. Lerch

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9643-8263; OpenAlex author ID A5101644008. Sources: ClinicalTrials.gov.

Their work

Papers
39 (first author 0, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
164
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 4 papers · 2012: 4 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 5 papers · 2017: 2 papers · 2018: 6 papers · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: 5 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 39

  1. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  2. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  3. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  4. DNA Polymerase Theta Plays a Critical Role in Pancreatic Cancer Development and Metastasis. Co-author DOI 10.3390/cancers14174077↗
  5. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/cancers14184467↗
  6. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/ijms23084295↗
  7. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell L… Co-author DOI 10.3390/ijms23084409↗
  8. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenoc… Co-author DOI 10.1053/j.gastro.2021.05.055↗
  9. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  10. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  11. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  12. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  13. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  14. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Co-author DOI 10.1038/s41395-018-0395-y↗
  15. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  16. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer. Co-author DOI 10.1016/j.cca.2017.12.008↗
  17. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  18. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  19. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  20. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  21. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Last author DOI 10.1136/gutjnl-2016-312432↗
  22. Copy number variants and VNTR length polymorphisms of the carboxyl-ester lipase (CEL) gene as risk factors in pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.10.006↗
  23. Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges. Co-author DOI 10.1152/ajpgi.00138.2017↗
  24. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Co-author DOI 10.1016/j.pan.2016.03.005↗
  25. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1038/bjc.2016.277↗
  26. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311393↗
  27. Nutrition in Pancreatic Cancer: A Review. Co-author DOI 10.1159/000442873↗
  28. Development of Pancreatic Cancer: Targets for Early Detection and Treatment. Co-author DOI 10.1159/000445233↗
  29. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  30. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxaglipti… Last author DOI 10.2337/dc13-2546↗
  31. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  32. The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Co-author DOI 10.1053/j.gastro.2011.10.026↗
  33. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2011-300060↗
  34. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1136/gutjnl-2011-300850↗
  35. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Last author DOI 10.1186/1475-2891-11-52↗
  36. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluor… Co-author DOI 10.1124/dmd.110.033613↗
  37. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Last author DOI 10.1159/000323933↗
  38. A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. Co-author DOI 10.1159/000329413↗
  39. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. Co-author DOI 10.1186/1471-2407-11-40↗

Trials 1

  1. L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN) Principal investigator NCT01330823↗

Closest collaborators

The 25 strongest of 164 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia V. Mayerle · 27 shared papers, 2011–2022 · strength 1.52
  2. Frank Ulrich Weiß · 19 shared papers, 2011–2022 · strength 1.30
  3. John P. Neoptolemos · 10 shared papers, 2016–2022 · strength 0.70
  4. Christopher Michael Halloran · 10 shared papers, 2016–2021 · strength 0.66
  5. Ujjwal Mukund Mahajan · 8 shared papers, 2016–2022 · strength 0.61
  6. William Greenhalf · 8 shared papers, 2016–2021 · strength 0.54
  7. Georg Beyer · 6 shared papers, 2018–2022 · strength 0.51
  8. Markus Wolfgang Büchler · 8 shared papers, 2012–2021 · strength 0.48
  9. Eithne Costello · 7 shared papers, 2016–2021 · strength 0.46
  10. Paula Ghaneh · 7 shared papers, 2016–2021 · strength 0.45
  11. Daniel H. Palmer · 7 shared papers, 2016–2021 · strength 0.43
  12. Yixuan Ma · 3 shared papers, 2022 · strength 0.40
  13. Dietmar Zechner · 3 shared papers, 2022 · strength 0.40
  14. Hugo Murua Escobar · 3 shared papers, 2022 · strength 0.40
  15. Ivonne Regel · 4 shared papers, 2018–2022 · strength 0.36
  16. Elisabetta Goni · 4 shared papers, 2018–2022 · strength 0.34
  17. Alan Anthoney · 5 shared papers, 2018–2021 · strength 0.33
  18. Bengt L. G. Glimelius · 5 shared papers, 2018–2021 · strength 0.33
  19. Juan W. Valle · 5 shared papers, 2018–2021 · strength 0.33
  20. Robert Grützmann · 3 shared papers, 2018–2022 · strength 0.27
  21. Christian P. Pilarsky · 3 shared papers, 2018–2022 · strength 0.27
  22. Marius Distler · 3 shared papers, 2018–2022 · strength 0.27
  23. David Goldstein · 4 shared papers, 2018–2021 · strength 0.27
  24. Niall Christopher Tebbutt · 4 shared papers, 2018–2021 · strength 0.27
  25. Jorg H. Kleeff · 4 shared papers, 2016–2020 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.